Verona Pharma plc Dr. Martin Edwards Joins Verona Pharma As Non-Executive Director
March 21 2019 - 3:00AM
UK Regulatory
TIDMVRP
LONDON, March 21, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that Dr. Martin Edwards will join
the board as a Non-Executive Director, effective from 1 April 2019.
Dr. Edwards has over three decades of experience in the pharmaceutical
and venture capital industries. He is currently Senior Partner of Novo
Holdings, where he has held various positions since 2003. Novo Holdings
has a shareholding of 11.76% in Verona Pharma. Notwithstanding this, our
Board of Directors considers Dr. Edwards to be an independent director
under UK and US corporate governance rules.
Commenting on the appointment, Dr. David Ebsworth, Chairman of Verona
Pharma, said: "We are delighted to welcome Martin to our Board. His
substantial expertise in the sector, along with his unique leadership
insights and perspective, will be valuable as we continue to advance
ensifentrine into late-stage clinical development."
In addition to his role on the Verona Pharma Board, Dr. Edwards is
Chairman of the Board of Directors of Vantia Therapeutics Ltd and a
member of the Board of Directors of F2G Ltd, Harmony Biosciences Inc,
Inozyme Pharma Inc, Karus Therapeutics Ltd, Nuvelution Pharma Inc and
Tarsa Therapeutics Inc.
From 1998 to 2003, Dr. Edwards was CEO of ReNeuron Holdings plc and
completed the company's initial public offering in 2000. Previously, he
was Corporate VP and Global Head of Drug Development for Novo Nordisk
A/S, where he led all aspects of pre-clinical and clinical drug
development. Earlier in his career, he worked as VP Pharmacology and
Medical Affairs of ZymoGenetics Inc and as Senior VP for Medical Affairs
at Novo Nordisk USA.
Dr. Edwards trained in physiology and medicine at the University of
Manchester. He is a Member of the Royal College of Physicians, a Member
with distinction of the Royal College of General Practitioners, a Fellow
of the Faculty of Pharmaceutical Medicine and holds a MBA from the
University of Warwick.
Schedule Two information regarding Dr. Martin Edwards
Martin William Edwards (62) holds or has held the following
directorships and partnerships in the last five years:
Current Directorships memberships: Past Directorships memberships:
F2G Ltd, Harmony Biosciences Inc, Inozyme Pharma Inc, Acacia Pharma Group, CoLucid Inc,
Karus Therapeutics Ltd, Nuvelution Pharma Inc, Tarsa E3 Bio Ltd, Funxional Therapeutics Ltd, KalVista Pharmaceuticals
Therapeutics Inc, Vantia Therapeutics Ltd Ltd (now Inc), NeRRe Therapeutics Ltd, Stargazer Pharmaceuticals
Ltd
Except for the information disclosed above, there is no other
information in relation to Dr. Edwards required to be disclosed pursuant
to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
About Verona Pharma and ensifentrine
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, ensifentrine, is an investigational
first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase
3 and 4 that is designed to act as both a bronchodilator and an
anti-inflammatory agent in a single compound. Ensifentrine has been
studied via the nebulized route of administration in clinical trials
involving more than 800 subjects. The nebulized formulation of
ensifentrine has significantly improved lung function, including
enhanced peak FEV(1) , reduced lung hyperinflation and faster
onset-of-action when used alone or as an add-on treatment to some of the
most commonly used COPD therapies, including tiotropium (Spiriva(R) ),
tiotropium/olodaterol fixed-dose combination, ipratropium, and
albuterol. In addition, ensifentrine has shown anti-inflammatory effects
in a standard challenge study with COPD-like inflammation in humans.
Ensifentrine was well tolerated in these trials. Verona Pharma is
developing ensifentrine for the treatment of COPD, cystic fibrosis and
asthma.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
March 21, 2019 03:00 ET (07:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024